TNF and COVID-19: On the other hand, the COVID-19 Global Rheumatology Alliance studied the demographic and clinical factors associated with COVID-19 hospitalization in rheumatic patients and found that a ≥10 mg/day glucocorticoid dose was associated with a higher odds of hospitalization (OR 2.05, 95% CI 1.06–3.96), whereas anti-TNFα present a decreased incidence or hospitalizations (OR 0.40, 95% CI 0.19–0.81).